[HTML] mdpi.com

[HTML][HTML] Uremic toxins and cardiovascular risk in chronic kidney disease: what have we learned recently beyond the past findings?

C El Chamieh, S Liabeuf, Z Massy - Toxins, 2022 - mdpi.com
Patients with chronic kidney disease (CKD) have an elevated prevalence of atheromatous
(ATH) and/or non-atheromatous (non-ATH) cardiovascular disease (CVD) due to an array of …
被引用次数：28 相关文章
[PDF] researchgate.net

[PDF][PDF] Uremic Toxins and Cardiovascular Risk in Chronic Kidney Disease: What Have We Learned Recently beyond the Past Findings? Toxins 2022, 14, 280

C El Chamieh, S Liabeuf, Z Massy - 2022 - researchgate.net
Patients with chronic kidney disease (CKD) have an elevated prevalence of atheromatous
(ATH) and/or non-atheromatous (non-ATH) cardiovascular disease (CVD) due to an array of …

Uremic Toxins and Cardiovascular Risk in Chronic Kidney Disease: What Have We Learned Recently beyond the Past Findings?

C El Chamieh, S Liabeuf, Z Massy - Toxins, 2022 - u-picardie.hal.science
Patients with chronic kidney disease (CKD) have an elevated prevalence of atheromatous
(ATH) and/or non-atheromatous (non-ATH) cardiovascular disease (CVD) due to an array of …

Uremic Toxins and Cardiovascular Risk in Chronic Kidney Disease: What Have We Learned Recently beyond the Past Findings?

C El Chamieh, S Liabeuf, Z Massy - Toxins, 2022 - search.proquest.com
Patients with chronic kidney disease (CKD) have an elevated prevalence of atheromatous
(ATH) and/or non-atheromatous (non-ATH) cardiovascular disease (CVD) due to an array of …

Uremic Toxins and Cardiovascular Risk in Chronic Kidney Disease: What Have We Learned Recently beyond the Past Findings?

C El Chamieh, S Liabeuf, Z Massy - Toxins, 2022 - hal.science
Patients with chronic kidney disease (CKD) have an elevated prevalence of atheromatous
(ATH) and/or non-atheromatous (non-ATH) cardiovascular disease (CVD) due to an array of …

Uremic Toxins and Cardiovascular Risk in Chronic Kidney Disease: What Have We Learned Recently beyond the Past Findings?

C El Chamieh, S Liabeuf, Z Massy - Toxins, 2022 - pubmed.ncbi.nlm.nih.gov
Patients with chronic kidney disease (CKD) have an elevated prevalence of atheromatous
(ATH) and/or non-atheromatous (non-ATH) cardiovascular disease (CVD) due to an array of …

Uremic Toxins and Cardiovascular Risk in Chronic Kidney Disease: What Have We Learned Recently beyond the Past Findings?

C El Chamieh, S Liabeuf, Z Massy - Toxins, 2022 - inria.hal.science
Patients with chronic kidney disease (CKD) have an elevated prevalence of atheromatous
(ATH) and/or non-atheromatous (non-ATH) cardiovascular disease (CVD) due to an array of …

Uremic Toxins and Cardiovascular Risk in Chronic Kidney Disease: What Have We Learned Recently beyond the Past Findings?

C El Chamieh, S Liabeuf, Z Massy - Toxins, 2022 - u-paris.hal.science
Patients with chronic kidney disease (CKD) have an elevated prevalence of atheromatous
(ATH) and/or non-atheromatous (non-ATH) cardiovascular disease (CVD) due to an array of …
[HTML] nih.gov

[HTML][HTML] Uremic Toxins and Cardiovascular Risk in Chronic Kidney Disease: What Have We Learned Recently beyond the Past Findings?

C El Chamieh, S Liabeuf, Z Massy - Toxins, 2022 - ncbi.nlm.nih.gov
Patients with chronic kidney disease (CKD) have an elevated prevalence of atheromatous
(ATH) and/or non-atheromatous (non-ATH) cardiovascular disease (CVD) due to an array of …

Uremic Toxins and Cardiovascular Risk in Chronic Kidney Disease: What Have We Learned Recently beyond the Past Findings?

C El Chamieh, S Liabeuf, Z Massy - Toxins, 2022 - search.ebscohost.com
Patients with chronic kidney disease (CKD) have an elevated prevalence of atheromatous
(ATH) and/or non-atheromatous (non-ATH) cardiovascular disease (CVD) due to an array of …